Enoticumab is used as an anti-DLL4 monoclonal antibody to inhibit tumor growth by targeting the DLL4 ligand of the Notch signaling pathway; it demonstrates in vivo antitumor activity in ovarian xenograft models, achieving 86% and 83% tumor growth inhibition in subcutaneous TOV-112D and intraperitoneal A2780 human tumor xenograft mouse models, respectively, when administered at 2.5 mg/kg once weekly.